openPR Logo
Press release

CROS NT appoints new Vice President for Germany

07-29-2010 09:00 AM CET | Health & Medicine

Press release from: CROS NT

CROS NT (CRO) announces the appointment of Frank Freischläger as Vice President (VP) for CROS DE GmbH, the German affiliate of CROS NT. As a VP at CROS DE he will be responsible for all aspects, which is focused on successful clinical trial activities.

CROS is very excited to adding Mr. Freischläger's depth of industry expertise to the CROS team. "Bringing someone of Frank's knowledge to an already strong team will further strengthen our ability to grow in the right direction", said Dr. Paolo Morelli, General Manager of the CROS NT Group.

Mr. Freischläger has more than 20 years of clinical research experience in the pharmaceutical and CRO industries. He was leading groups in Clinical Data Management, Biostatistics & Programming, Medical Writing and Information Services for international CROs in Germany, the UK, Spain, Greece, Czech Republic and India. His experience includes a great variety of systems environments, therapeutic areas, clinical phases and trial designs. He holds a degree in statistics from the University of Dortmund.

CROS is a contract research organization offering a wide range of clinical research services to the pharmaceutical, biotechnology and medical devices industries. From Phase I to Phase IV, CROS focuses on delivering the highest quality data and meeting projected timelines.

To learn more about CROS, please visit http://www.crosnt.com, contact us by email info@crosnt.com or call our headquarters at +39 045 8202666.

CROS NT provides outsourced CDM, statistical, eCRF, ePRO and Hosting services across all phases of drug development. CROS NT offers global Pharmacovigilance solution for clinical safety and postmarket surveillance. With sophisticated technologies and processes CROS delivers on every project's specific requirements with a group of professionals.

CROS NT srl
Via Germania 2
37135 Verona
Italy

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CROS NT appoints new Vice President for Germany here

News-ID: 139677 • Views:

More Releases from CROS NT

11-26-2010 | Health & Medicine
CROS NT
CROS NT WINS A "BEST PRESENTATION" AT PhUSE 2010
Verona, Italy (26 NOVEMBER 2010) – Stefano Vezzoli, part of CROS NT’s highly qualified and experienced biostatistics team, won Best Presentation in the area of Statistics and Pharmacokinetics at the Pharmaceutical Users Software Exchange (PhUSE) conference in Berlin, Germany. Vezzoli’s presentation was titled “Inference for the Location Shift in 3x3 Crossover Studies: the Median-Scaling Method”. Vezzoli’s Paper Abstract In the case of non-normal study outcomes, a nonparametric approach may be used
CROS NT GROUP TO ATTEND THIRD ANNUAL ONCOLOGY CLINICAL TRIALS
11-23-2010 | Health & Medicine
CROS NT
CROS NT GROUP TO ATTEND THIRD ANNUAL ONCOLOGY CLINICAL TRIALS
Verona, Italy (23 NOVEMBER 2010) – The German subsidiary of the CROS NT Group, CROS DE GmbH, will be present at the Third Annual Oncology Clinical Trials in Munich, Germany from 29 November through 1 December. The therapeutic area of oncology is one of CROS NT’s areas of excellence regarding clinical trial experience, and the CROS DE management team is at the forefront of clinical trial consultancy in this field.
CROS NT Group launches Arithmos s.r.l. to keeping up with the new Innovation’s Challenges
CROS NT Group launches Arithmos s.r.l. to keeping up with the new Innovation’s …
CROS NT Group launches Arithmos s.r.l., a start up company created at the beginning of 2010 with the aim to play an active role as information technology service provider within the pharmaceutical and biotechnology environment. Inheriting CROS NT’s 15 years experience and developing a strong sensibility for innovation investments, today Arithmos is a valuable partner to optimize companies performances and accelerate their growth into the market in an accurate, safe and
CROS NT Announces its Expansion into German Market Creating CROS DE GmbH
CROS NT Announces its Expansion into German Market Creating CROS DE GmbH
CROS NT is pleased to announce its expansion into Europe through the creation of CROS DE GmbH, a new wholly-owned subsidiary based in Augsburg, Germany. The company, born from the experience of a German-based CRO, Estimate GmbH, is specialized in providing statistical services to pharmaceuticals and biotechnology industries. Estimate enrich CROS NT with its expertise and a particular excellence concerning the oncology and dermatology-related research. Estimate was found in 1992

All 5 Releases


More Releases for CRO

Oncology Based Preclinical CRO Market 2021 | Detailed Report
The Oncology Based Preclinical CRO research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information about the
Contract Research Organization (CRO) Market 2021 | Detailed Report
The Contract Research Organization (CRO) research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information about the
Pracedo Promote Ellie Copp To CRO
Pracedo, a Mashfrog Group company that provides Salesforce consultancy and digital transformation to charities, NGOs, and enterprise customers, promotes Ellie Copp to Chief Revenue Officer. Pracedo announced Ellie Copp as its new Chief Revenue Officer (CRO). Ellie joined Pracedo in 2019 and most recently held the position of Sales and Marketing Director. As CRO, she will continue to lead the commercial teams by overseeing all revenue-generating activities as Pracedo continues
Global CRO Services Market Size, Status and Forecast
This report studies the global CRO Services market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global CRO Services market by companies, region, type and end-use industry. Contract research organization (CRO) provide clinical trial and other research support services for the pharmaceutical, biotechnology, medical device industries and also serve government institutions, foundations and universities. Get sample copy of the report: www.marketdensity.com/contact?ref=Sample&reportid=75298 Table of Contents: Table of Contents Global
CRO Services Industry Worldwide Growth and Development
ReportsWeb.com has announced the addition of the “Global CRO Services Market Size, Status and Forecast 2022” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. This report studies the global CRO Services market, analyzes and researches the CRO Services development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in
Partnership factors in sponsor – CRO relationships
Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market. CRO’s have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money. There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate